Menu
Not yet recruiting NCT07466537

Efficacy and Safety of Intravaginal EMS Treatments in Women With Exclusive or Predominant Stress Urinary Incontinence

No phase Interventional Stress Urinary Incontinence (SUI)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Electrical intravaginal muscle stimulation.
Who it may be relevant to
Registry conditions: Stress Urinary Incontinence (SUI). Basic parameters: from 18 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Efficacy and Safety of 6 Intravaginal EMS Treatments in Women With Exclusive or Predominant Stress Urinary Incontinence

Overview

The investigator wants to evaluate the efficacy of a specific intravaginal Electrical Muscle Stimulation (EMS), in the treatment of exclusive or predominant stress urinary incontinence (SUI) symptoms in women. The investigator's aim is to determine the device's impact (the device is VTone) on reducing urinary incontinence episodes and on improving women's quality of life.

Interventions

  • Device Electrical intravaginal muscle stimulation
    The device includes an ogival, circular body, with a handle at one end of the body, a head at the other end of the body. The head includes a substantially flat, metallic surface. The device and the head are sized and configured to be received in a patient's vagina. The device should be used with gel. Patients will be trated with six sessions (planned once a week for a total of six week).

Primary outcome measures

  • Variation in patient bladder voiding diaries' results at follow up visits versus baseline [Time frame: Follow up visits: 1 month and 3 months after the last session of treatment]

Eligibility criteria

Inclusion criteria

  • Women with minimum age of 18 years .
  • Documented clinical diagnosis of exclusive or predominant stress urinary incontinence.
  • Willingness to comply with study procedures and follow-up visits.
  • Signed informed consent to participate in the study.
  • BMI </= 30.

Exclusion criteria

  • Pacemaker or internal defibrillator, or any other metallic or electronic implant anywhere in the body.
  • Any permanent implant or an injected chemical substance in the treatment area.
  • Superficial areas that have been injected with hyaluronic acid (HA)/collagen/fat injections or other augmentation methods with bio-material during last 6 months.
  • Current or history of cancer, or current condition of any other type of cancer, or premalignant moles.
  • Severe concurrent conditions, such as cardiac disorders, sensory disturbances, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
  • Pregnancy
  • Impaired immune system due to immunosuppressive diseases such as AIDS and HIV or use of immunosuppressive medications.
  • Patients with a history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.
  • Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization.
  • Any active condition in the treatment area, such as sores, eczema, and rash.
  • History of bleeding coagulopathies or use of anticoagulants in the last 10 days, as per the practitioner's discretion.
  • Non-Italian speakers
  • Severely impaired mobility or cognition
  • Spinal cord injury or advanced/severe neurologic condition including Multiple Sclerosis, Parkinson's Disease
  • Repair of pelvic organ prolapse or incontinence procedure in the previous 6 months
  • Ongoing complications of prior anti-incontinence surgery
  • Received intravesical botulinum injection within the previous 12 months
  • History of an implanted nerve stimulator for incontinence
  • History of prior sling or vaginal mesh placement
  • Previous diagnosis of interstitial cystitis, bladder cancer, or chronic pelvic pain
  • Current participation in any other conflicting interventional or treatment study
  • Active urinary tract or vaginal infection
  • Current hydronephrosis or hydroureter
  • Bladder outflow obstruction
  • Active pelvic organ malignancy
  • Urethral obstruction
  • Urinary retention or prolonged catheter use
  • Less than 12 months post-partum
  • Untreated symptomatic urinary tract infection
  • Unevaluated hematuria
  • Not available for follow-up in 6 months
  • Participation in other research trials that could influence results of this study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07466537 · STONE

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗